(Q48750580)

15 February 2018

title

Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. (English)

1 reference

15 February 2018

Heart failure with preserved ejection fraction

main subject

heart failure

0 references

patient

0 references

1 reference

1 reference

3

1 reference

15 February 2018

Christoph Herrmann-Lingen

11

Christoph Herrmann-Lingen

1 reference

15 February 2018

13

Gerd Hasenfuss

1 reference

15 February 2018

15

Wendy Gattis Stough

1 reference

15 February 2018

10

Carsten Tschöpe

1 reference

15 February 2018

Burkert Pieske

16

Burkert M Pieske

1 reference

15 February 2018

Elisabeth Kraigher-Krainer

6

Elisabeth Kraigher-Krainer

1 reference

15 February 2018

Hans-Dirk Düngen

9

Hans-Dirk Düngen

1 reference

15 February 2018

author name string

Frank Edelmann

1

1 reference

15 February 2018

Volker Holzendorf

2

1 reference

15 February 2018

Kathleen Nolte

4

1 reference

15 February 2018

Albrecht G Schmidt

5

1 reference

15 February 2018

André Duvinage

7

1 reference

15 February 2018

Ines Unkelbach

8

1 reference

15 February 2018

Martin Halle

12

1 reference

15 February 2018

Götz Gelbrich

14

1 reference

15 February 2018

publication date

24 November 2014

1 reference

15 February 2018

European Journal of Heart Failure

published in

1 reference

15 February 2018

volume

17

1 reference

15 February 2018

issue

2

1 reference

15 February 2018

page(s)

214-223

1 reference

15 February 2018

The pathophysiology of heart failure with preserved ejection fraction: from molecular mechanisms to exercise haemodynamics

cites work

1 reference

New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment

21 January 2018

1 reference

Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment

21 January 2018

1 reference

Galectin-3 in heart failure with preserved ejection fraction

21 January 2018

1 reference

Galectin-3 in cardiac remodeling and heart failure

21 January 2018

1 reference

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction

21 January 2018

1 reference

Galectin-3: a novel mediator of heart failure development and progression

21 January 2018

1 reference

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study

21 January 2018

1 reference

Galectin-3 regulates myofibroblast activation and hepatic fibrosis

21 January 2018

1 reference

The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.

21 January 2018

1 reference

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction

21 January 2018

1 reference

The fibrosis marker galectin-3 and outcome in the general population.

21 January 2018

1 reference

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study

21 January 2018

1 reference

Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure

21 January 2018

1 reference

Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community

21 January 2018

1 reference

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial

21 January 2018

1 reference

Rationale and design of the 'aldosterone receptor blockade in diastolic heart failure' trial: a double-blind, randomized, placebo-controlled, parallel group study to determine the effects of spironolactone on exercise capacity and diastolic function

21 January 2018

1 reference

Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure

21 January 2018

1 reference

Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices

21 January 2018

1 reference

Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure

21 January 2018

1 reference

Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure

21 January 2018

1 reference

Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction

21 January 2018

1 reference

Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH.

21 January 2018

1 reference

The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism

21 January 2018

1 reference

Aldosterone and end-organ damage

21 January 2018

1 reference

7 January 2021

Galectin-3 in heart failure: high levels are associated with all-cause mortality

1 reference

7 January 2021

Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

1 reference

7 January 2021

Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial

1 reference

7 January 2021

Identifiers

DOI

10.1002/EJHF.203

1 reference

15 February 2018

1 reference

15 February 2018